Aurinia: Paying For Growth That Is Already Fading
Vor Biopharma Inc. VOR
$19.32
▼ -3.30%
($-0.66)
⬇️ Below Yest. Low
Open
$19.77
Prev Close
$19.98
Day Range
$19.26 – $20.35
52W Range
$6.50 – $26.00
Market Cap
$1.21B
P/E (TTM)
0.93
Beta
1.75
EPS (TTM)
$77.17
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-05 |
| Shares Out. | 61,430,000 |
| Website | vorbio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 76 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$86.7M |
| Free Cash Flow | -$119.7M |
| Total Assets | $496.3M |
| Total Liabilities | $633.5M |
| Equity | -$137.2M |
About Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Vor Biopharma Inc. is a publicly traded company under the ticker symbol VOR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-11-01)